Literature DB >> 35152142

Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial".

Richard R Riker1, David J Gagnon2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35152142      PMCID： PMC9064955          DOI： 10.1016/j.jcrc.2022.153995

Source DB:  PubMed          Journal:  J Crit Care        ISSN： 0883-9441            Impact factor:   4.298


× No keyword cloud information.
  9 in total

1.  A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study.

Authors:  Rahul Costa-Pinto; Zhen-Ti Yong; Fumitaka Yanase; Chelsea Young; Alastair Brown; Andrew Udy; Paul J Young; Glenn Eastwood; Rinaldo Bellomo
Journal:  J Crit Care       Date:  2021-11-18       Impact factor: 3.425

2.  Feasibility, Utility, and Safety of Midodrine During Recovery Phase From Septic Shock.

Authors:  Micah R Whitson; Edwin Mo; Tasnima Nabi; Lauren Healy; Seth Koenig; Mangala Narasimhan; Paul H Mayo
Journal:  Chest       Date:  2016-03-04       Impact factor: 9.410

3.  Midodrine for the weaning of vasopressor infusions.

Authors:  L B Poveromo; E L Michalets; S E Sutherland
Journal:  J Clin Pharm Ther       Date:  2016-03-04       Impact factor: 2.512

4.  Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series.

Authors:  Mahrukh S Rizvi; Vrinda Trivedi; Faria Nasim; Erica Lin; Rahul Kashyap; Nicole Andrijasevic; Ognjen Gajic
Journal:  Crit Care Med       Date:  2018-07       Impact factor: 7.598

5.  Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions.

Authors:  Alexander R Levine; Matthew J Meyer; Edward A Bittner; Sheri Berg; Rebecca Kalman; Anne B Stanislaus; Cheryl Ryan; Stephanie A Ball; Matthias Eikermann
Journal:  J Crit Care       Date:  2013-07-08       Impact factor: 3.425

6.  A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.

Authors:  R A Wright; H C Kaufmann; R Perera; T L Opfer-Gehrking; M A McElligott; K N Sheng; P A Low
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

7.  Hemodynamic Effects of an Increased Midodrine Dosing Frequency.

Authors:  Shea A Macielak; Nicholas J Vollmer; Natalie A Haddad; Christoph G S Nabzdyk; Scott D Nei
Journal:  Crit Care Explor       Date:  2021-04-26

8.  Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.

Authors:  Peter Santer; Matthew H Anstey; Maria D Patrocínio; Bradley Wibrow; Bijan Teja; Denys Shay; Shahzad Shaefi; Charles S Parsons; Timothy T Houle; Matthias Eikermann
Journal:  Intensive Care Med       Date:  2020-09-03       Impact factor: 17.440

9.  Potential risks in using midodrine for persistent hypotension after cardiac surgery: a comparative cohort study.

Authors:  Jan-Alexis Tremblay; Philippe Laramée; Yoan Lamarche; André Denault; William Beaubien-Souligny; Anne-Julie Frenette; Loay Kontar; Karim Serri; Emmanuel Charbonney
Journal:  Ann Intensive Care       Date:  2020-09-14       Impact factor: 6.925
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.